Moderna, Inc. (MRNA): Revenue
$1.94B
Year ended 2025-12-31
$2.23B
Trailing 12 months to 2026-06-30
-53.4%
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.94B | -39.9% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $3.24B | -52.7% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $6.85B | -64.4% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $19.26B | +4.3% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $18.47B | n/a | 2024-02-23, From 2021-01-01 |
| No annual figure between 2019-12-31 and 2021-12-31. | |||
| 2019-12-31 | $60.21M | n/a | 2020-02-27, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | $1.94B | -39.9% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $2.09B | +5.7% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.32B | +7.0% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $1.40B | +37.6% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $2.86B | +21.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.22B | -0.4% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.12B | +64.7% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $874.84M | +94.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $738.26M | +16.4% |
Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗